Chronic rhinosinusitis (CRS) is a surprisingly common but under-recognized disease that affects nearly one billion people worldwide, or about 12% of the population. Defined as a long-lasting ...

The U.S. Food and Drug Administration approved Tezspire (tezepelumab-ekko; Amgen) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in ...

In an Italian study involving more than 900 patients with chronic rhinosinusitis with nasal polyps (CRSwNP), dupilumab reduced NP scores and alleviated nasal obstruction at 2 years. Over 91% of ...

The first head-to-head randomized clinical trial to compare biologics in severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma showed an advantage to dupilumab (Dupixent) over ...

A randomized placebo-controlled Finnish study showed that aspirin therapy does not provide significant relief for people suffering from chronic rhinosinusitis with nasal polyps who are hypersensitive ...

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc.'s (NASDAQ:AMGN) Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for adult patients with chronic rhinosinusitis with ...

Food and Drug Administration has approved Amgen and AstraZeneca's drug for a type of chronic sinus infection, the drugmakers ...